Table 1 Study population characteristics, N=84
Variable | Median (IQR) or n/N(%) |
|---|---|
Age (years) | 36 (32–42) |
Female n/N (%) | 72/84 (86) |
Race n/N (%) | |
Black | 84/84 (100) |
Weight (kg) | 69 (60–82) |
Body mass index (kg/m2) | 26 (23–32) |
Waist: hip ratio | 0.88 (0.82-0.94) |
Skin fold thickness (mm) | |
Triceps | 17 (11–25) |
Abdomen | 24 (17–40) |
Thigh | 30 (17–46) |
Calf | 16 (9–21) |
Blood pressure mmHg | 108/72 (102/66-119/77) |
CD4 count (cells/ mm3) | |
Pre-ART | 103 (37–140) |
Current | 468 (291–623) |
Current viral load | |
Proportion with <400 copies/mL (%)* | 64/74 (86) |
Duration on lopinavir (months) | 19 (9–29) |
Concurrent ART n/N (%) | |
Zidovudine/didanosine | 51/84 (61) |
Zidovudine/lamivudine | 17/84 (20) |
Stavudine/lamivudine | 10/84 (12) |
Efavirenz | 4/84 (5) |
Nevirapine | 2/84 (2) |
Metabolic parameters (mmol/L) | |
Fasting cholesterol | 4.3 (3.7 to 5.3) |
Fasting triglycerides | 1.3 (0.9 to 1.8) |
Fasting glucose | 5.2 (4.7 to 5.7) |
2 hour glucose | 6.3 (5.4 to 8.1) |